Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212-489-2100

Fax: 212-489-2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, New York, United States

Zero11 Aug. 7 at 11:46 AM

$DCTH so quiet lol

1 · Reply

JarvisFlow Aug. 7 at 11:30 AM

HC Wainwright & Co. updates rating for Delcath Systems ( $DCTH ) to Buy, target set at 29 → 31.

0 · Reply

Dryrr Aug. 7 at 10:26 AM

$DCTH H.C. from 29>31$

1 · Reply

Dryrr Aug. 7 at 6:56 AM

$DCTH stock was in a massive downtrend, it didnt break out yesterday. lets see if it does this week

0 · Reply

RemitTekram Aug. 7 at 3:23 AM

$DCTH Which looks like the shitco now?

1 · Reply

alexpitti Aug. 7 at 2:52 AM

this really was a great call and a solid report. only a slight decline in guidance due to slightly slower center activation $DCTH

0 · Reply

alexpitti Aug. 7 at 2:51 AM

Delcath said they will increase usage just by increasing hours at the centers and training more docs. 2 readouts in 2027. working on 2 more indications for trials/studies. CHOPIN in 2 months. $81 million in cash. will profitable in all qs. only 50% volume taking the 23.1% price cut. usage should be up at discounted centers. usage up per center $DCTH

1 · Reply

Zero11 Aug. 6 at 11:38 PM

$DCTH moomoo updated

0 · Reply

mar99 Aug. 6 at 10:54 PM

$DCTH Shorts can play all the games they want and drive the price where they want for now. None of that changes the fact that this company is firing on all cylinders, is very well run, is very cheap and most likely is heading much higher at some point. Thankfully they have all the cash they need so there is nothing the shorts can do to change any of that.

1 · Reply

MHuntswollen Aug. 6 at 8:28 PM

$DCTH $10.39 is the level of support. Hopefully it holds up.

0 · Reply

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 8:00 AM EDT - 1 day ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 8 days ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 25, 2025, 4:01 PM EDT - 12 days ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 23, 2025, 4:01 PM EDT - 14 days ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jun 12, 2025, 8:36 AM EDT - 2 months ago

Delcath Systems: Growing Fast, But Business Model Is Fragile

May 22, 2025, 7:00 AM EDT - 2 months ago

Delcath Systems Issues Full Year 2025 Guidance

May 18, 2025, 8:25 AM EDT - 2 months ago

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

May 15, 2025, 4:30 PM EDT - 2 months ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 3 months ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 10:55 AM EDT - 3 months ago

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 3 months ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 3 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 3 months ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 4 months ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 2, 2025, 11:49 AM EDT - 4 months ago

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Mar 24, 2025, 4:01 PM EDT - 4 months ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 5 months ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 2:17 PM EST - 5 months ago

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 5 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 5 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 6 months ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 6 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 6 months ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 7 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 7 months ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2024, 8:00 AM EST - 7 months ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 2, 2024, 8:30 AM EST - 8 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Nov 20, 2024, 7:50 AM EST - 9 months ago

Delcath Begins Platform Expansion With Two Phase 2 Trials

Nov 18, 2024, 7:09 AM EST - 9 months ago

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Nov 8, 2024, 12:30 PM EST - 9 months ago

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:00 AM EST - 9 months ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Nov 1, 2024, 4:01 PM EDT - 9 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Oct 25, 2024, 8:30 AM EDT - 10 months ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 17, 2024, 8:30 AM EDT - 10 months ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Sep 16, 2024, 8:30 AM EDT - 11 months ago

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Aug 23, 2024, 3:30 PM EDT - 1 year ago

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

TEM

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Aug 18, 2024, 10:03 PM EDT - 1 year ago

Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

Aug 6, 2024, 1:54 AM EDT - 1 year ago

Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

Aug 5, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems to Host Second Quarter 2024 Earnings Call

May 28, 2024, 9:30 AM EDT - 1 year ago

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

May 14, 2024, 2:16 PM EDT - 1 year ago

Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

Zero11 Aug. 7 at 11:46 AM

$DCTH so quiet lol

1 · Reply

JarvisFlow Aug. 7 at 11:30 AM

HC Wainwright & Co. updates rating for Delcath Systems ( $DCTH ) to Buy, target set at 29 → 31.

0 · Reply

Dryrr Aug. 7 at 10:26 AM

$DCTH H.C. from 29>31$

1 · Reply

Dryrr Aug. 7 at 6:56 AM

$DCTH stock was in a massive downtrend, it didnt break out yesterday. lets see if it does this week

0 · Reply

RemitTekram Aug. 7 at 3:23 AM

$DCTH Which looks like the shitco now?

1 · Reply

alexpitti Aug. 7 at 2:52 AM

this really was a great call and a solid report. only a slight decline in guidance due to slightly slower center activation $DCTH

0 · Reply

alexpitti Aug. 7 at 2:51 AM

1 · Reply

Zero11 Aug. 6 at 11:38 PM

$DCTH moomoo updated

0 · Reply

mar99 Aug. 6 at 10:54 PM

1 · Reply

MHuntswollen Aug. 6 at 8:28 PM

$DCTH $10.39 is the level of support. Hopefully it holds up.

0 · Reply

Damian23 Aug. 6 at 8:26 PM

$DCTH i didnt like the reversal at all, just finished the day almost flat, I think the stock will be punished until next Q to see if their margins are affected, and then shorts will come with an excuse to wait until next Q4.. Hard times..

1 · Reply

michaelsott Aug. 6 at 8:24 PM

$DCTH I can not wait until they get bought out by big pharma. It is only a matter of time. There are reasons beyond the know of why this is being kept down. Any ideas???

1 · Reply

Derekfarley Aug. 6 at 7:53 PM

$DCTH will close the day under every single moving average. Very bearish price action

1 · Reply

mar99 Aug. 6 at 7:53 PM

$DCTH Truly amazing from a high of 13.44. Shorts really know how to play their game.

0 · Reply

Greeny1968 Aug. 6 at 7:51 PM

$DCTH Really close!

1 · Reply

alexpitti Aug. 6 at 7:46 PM

both $VFC and $DCTH spike up over 20% at the open and closed up slightly. 2 in a row? what are the odds

1 · Reply

Hottehueh Aug. 6 at 7:46 PM

$DCTH one more round. buying again...

1 · Reply

Greeny1968 Aug. 6 at 7:45 PM

$DCTH Almost there!

0 · Reply

Zzzquil Aug. 6 at 7:44 PM

$DCTH yeesh, might as well completely close the gap at this point. If they didn’t beat last Q where would this be, single digits?

2 · Reply

Biotekman Aug. 6 at 7:38 PM

$DCTH It always surprises me when I see people complaining that a share price is too low. It's up to them to buy! Or else they shouldn't complain.

1 · Reply

Greeny1968 Aug. 6 at 7:37 PM

$DCTH I take it this drifts lower and lower until the next earnings?

1 · Reply

actuallysam Aug. 6 at 7:37 PM

$DCTH I also think this should be at $15, I will be looking at new analyst forecasts. I will be pleased if 2026 revenue is still expected at $135 million. If 2026 was cashflow even due to increased research, that would be enough.

0 · Reply

Market Cap	366.37M
Revenue (ttm)	37.21M
Net Income (ttm)	-26.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	34.15
Profit Margin	-70.92%
Debt to Equity Ratio	0.00

Volume	2,771,000
Avg Vol	728,350
Day's Range	N/A - N/A
Shares Out	34.83M
Stochastic %K	6%
Beta	0.82
Analysts	Strong Sell
Price Target	$24.40